Lilly's Obesity Windfall Raises Capital Allocation Dilemma
LLY sits 86% above its 52-week low of $623.78 on light trading volume (0.3× avg).
Summary
Eli Lilly's massive cash generation from obesity drugs like Zepbound and Foundayo is creating a capital allocation challenge. The article highlights the risk of value-destroying deals, citing Gilead, Moderna, and Pfizer as examples. Lilly has already been active, agreeing to buy AtaiBeckley for up to $3.8 billion on July 16 and pursuing a series of 2026 acquisitions in oncology, autoimmune diseases, and other areas. With a $1 trillion market cap, the pressure to deploy cash wisely is immense, and buybacks at current valuations would be dilutive to long-term value. This follows a string of positive clinical and coverage news, but now the focus shifts to execution risk in M&A.
At the time of this announcement, LLY was trading at $1,159.25 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.1T. The 52-week trading range was $623.78 to $1,249.45. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Reuters.